Biotechnology

Werewolf Therapeutics

Werewolf Therapeutics released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.28 (forecast USD -0.295)

Werewolf Therapeutics released FY2025 earnings on March 27 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.3269 (forecast USD -1.505)

Werewolf Therapeutics released FY2025 Q4 earnings on March 27 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1965 (forecast USD -0.345)

US Bank Securities Analyst Reiterates Buy Rating on Werewolf Therapeutics

Werewolf Therapeutics presented new preclinical data at the SITC annual meeting

Werewolf Therapeutics released FY2025 9 Months Earnings on November 4 (EST), actual revenue USD 0, actual EPS USD -1.1635

Werewolf Therapeutics released FY2025 Q3 earnings on November 4 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3599 (forecast USD -0.39)

Werewolf Therapeutics Inc. Reports Q3 Earnings and Updates Pipeline Progress

MPM BioVentures 2014, L.P. Sells Shares of Werewolf Therapeutics Inc.

Werewolf Therapeutics released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3999 (forecast USD -0.4783)

Werewolf Therapeutics released FY2025 Semi-Annual Earnings on August 14 (EST), with actual revenue of USD 0 and EPS of USD -0.8032

Millennium Management LLC reduced holdings in Werewolf Therapeutics, Inc.

Werewolf Therapeutics to Attend Jefferies Global Healthcare Conference

RA Capital Management Acquires Shares of Werewolf Therapeutics

Wedbush downgrades Werewolf Therapeutics price target

Werewolf Therapeutics released FY2025 Q1 earnings on May 8 EST, actual revenue USD 0 (forecast USD 300 K), actual EPS USD -0.4035 (forecast USD -0.4333)

Werewolf Therapeutics Developing Conditionally Activated Therapies

Luke Evnin sells common stock of Werewolf Therapeutics Inc.

Werewolf Therapeutics to Hold 2025 Virtual Annual Shareholder Meeting

Werewolf Therapeutics released FY2024 Q4 earnings on March 11 (EST), actual revenue 0 USD (forecast 301.59 K USD), actual EPS -0.4586 USD (forecast -0.4183 USD)

Co-Diagnostics

NewGenIvf

Liminatus Pharma

Netcapital

Agape ATP

Tradr 2X Long QBTS Daily ETF

Tradr 2X Long RGTI Daily ETF

Defiance Daily Target 2X Long RGTI ETF

Sunshine Biopharma

PicoCELA

Pinned News

置顶新闻

Luke Evnin Sells 22,184 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

HOWL

IBBQ

LABU

Luke Evnin, Director of Werewolf Therapeutics (NASDAQ:HOWL), sold 22,184 shares at $0.50 each, totaling $11,092, reducing his stake by 1.97%. Following this, he owns 1,104,312 shares valued at approximately $552,156. This transaction was part of a pre-arranged trading plan. Evnin has made several other sales recently, with varying amounts and prices. The stock is currently trading at $0.44, with a market cap of $21.29 million.

Market Beat

iShares Biotechnology ETF

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

JAZZ

ARKG

SBIO

Werewolf Therapeutics Inc. reported a Q1 2026 net loss of $13.53 million, improving from a loss of $18.09 million in Q1 2025. R&D expenses decreased to $8.18 million from $13.12 million. The company has $46.50 million in cash and equivalents. Additionally, Werewolf entered an asset purchase agreement with Jazz Pharmaceuticals for global rights to JZP898. The stock closed at $0.62, down 4.64%.

nasdaq

Jazz Pharma

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Nasdaq

Werewolf Reports Q1 Loss Of $13 Mln, Highlights Asset Purchase Agreement With Jazz

Earnings Watch

Werewolf Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0

Werewolf Therapeutics | 8-K: FY2026 Q1 EPS Beats Estimate at USD -0.28

WING

Wingstop pre-market down 8.65%; Werewolf Therapeutics pre-market up 7.97%; Inno pre-market up 74.25%; Sagtec Global pre-market up 45.31%; KalVista Pharmaceuticals pre-market up 38.62%

Price Alert

Wingstop

Inno

Sagtec Global

KalVista Pharma

Pre-market hot trades in US stocks: Wingstop pre-market down 8.65%; Werewolf Therapeutics pre-market up 7.97%

Werewolf Therapeutics Faces Nasdaq Delisting Risk After Falling Below $1 Minimum Bid Price

Tip Ranks

VG Health

iShares US Pharma

Health Care Select Sector SPDR

iShares Global Healthcare

Werewolf Therapeutics Faces Nasdaq Delisting Risk After Falling Below $1 Minimum Bid Price

AUTL

Before the market opens on March 27, 2026, several companies will report their earnings. Instil Bio (NASDAQ: TIL) will release its fourth-quarter earnings. BioXcel Therapeutics (NASDAQ: BTAI) is expected to announce a quarterly loss of $0.52 per share with revenue of $142 thousand. Legence (NASDAQ: LGN) is projected to report earnings of $0.02 per share and $618.01 million in revenue. Werewolf Therapeutics (NASDAQ: HOWL) anticipates a quarterly loss of $0.34 per share with $600 thousand in revenue. Humacyte (NASDAQ: HUMA) is estimated to post a loss of $0.13 per share on $1.44 million revenue. Autolus Therapeutics (NASDAQ: AUTL) is projected to report a loss of $0.38 per share.

Werewolf Therapeutics(HOWL.US)

Luke Evnin Sells 22,184 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Reports Q1 Loss Of $13 Mln, Highlights Asset Purchase Agreement With Jazz

Werewolf Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0

Werewolf Therapeutics | 8-K: FY2026 Q1 EPS Beats Estimate at USD -0.28

Pre-market hot trades in US stocks: Wingstop pre-market down 8.65%; Werewolf Therapeutics pre-market up 7.97%

Werewolf Therapeutics Faces Nasdaq Delisting Risk After Falling Below $1 Minimum Bid Price

Earnings Scheduled For March 27, 2026

Werewolf Therapeutics | 8-K: FY2025 Q4 Revenue: USD 0

Trending